Delivery Order SPE2DR25D1002-SPE2DR26FGH8T
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,957.42 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This non-competitive delivery order, with a firm fixed price structure, represents a child contract against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,548.41 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on October 21, 2025, with an ultimate completion date of October 22, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $31,867.64 to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 mL syringes. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 27, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made on a competitive, non-set-aside basis, reflecting AmerisourceBergen's established capability...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Dupixent 300 mg/2 ml syringes with a ceiling value of $32,376.84 under a firm fixed-price contract type. The delivery order, which represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), is to be fulfilled from the company's Conshohocken, Pennsylvania facility....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,840.94 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes. This firm fixed price, competitively awarded delivery order was issued on October 20, 2025, with an ultimate completion date of October 21, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Dupixent 300 mg/2 ml syringes with a ceiling value of $4,273.96 and an ultimate completion date of September 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The prime contractor, headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $34,000 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on October 20, 2025. This firm fixed-price delivery order, which is not set-aside, will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 21, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $11,966.22 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL syringes on September 5, 2025, with an ultimate completion date of September 8, 2025. This competitively awarded, firm fixed price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded a $9,986.53 delivery order contract to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on September 10, 2025, with an ultimate completion date of September 11, 2025. This competitively awarded, firm fixed-price contract requires performance at the contractor's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $62,693.40. This firm fixed-price delivery order, which is expected to be completed by August 4, 2025, will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation and represents a child contract under...
- SPE2DR25D1002Indefinite Delivery Contract
- SPE2DR25D1002-SPE2DR26FGH8TDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $10,655.01. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 23, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion and extending through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and established federal medical procurement vendor serving military and veteran healthcare systems. The delivery order supports DLA's medical supply chain operations, providing Dupixent, a pharmaceutical treatment used in dermatological and immunological conditions, to support federal healthcare needs. AmerisourceBergen's extensive portfolio of federal pharmaceutical contracts demonstrates its capability to compete successfully for medical supply awards and deliver critical medications and medical commodities across multiple therapeutic domains to the Defense Health Agency and other government healthcare systems. The competitively awarded nature of this contract underscores the contractor's ability to meet federal procurement requirements and pricing standards through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 10/22/25 |